Ratings by BofA Securities (Ying Huang)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 12/2/2022 | HOOKIPA Pharma Inc. | HOOK | Downgrade | Underperform (Buy) |
1.00 (0.84) |
-16% | Details | |
| 5/17/2022 | HOOKIPA Pharma Inc. | HOOK | Maintain | Buy (N/A) |
|
Details | ||
| 7/1/2020 | Y-mAbs Therapeutics | YMAB | Maintain | Buy (N/A) |
|
Details | ||
| 6/25/2020 | Puma Biotechnology | PBYI | New Coverage | Underperform (N/A) |
11.39 (8.04) |
-29.41% | Details | |
| 11/13/2019 | HOOKIPA Pharma Inc. | HOOK | Maintain | Buy (N/A) |
|
Details | ||
| 10/17/2019 | Amgen | AMGN | New Coverage | Neutral (N/A) |
204.66 (215.11) |
5.11% | Details | |
| 5/13/2019 | HOOKIPA Pharma Inc. | HOOK | New Coverage | Buy (N/A) |
13.84 (0.84) |
-93.93% | Details | |
| 5/6/2019 | Esperion Therapeutics | ESPR | Upgrade | Neutral (Underperform) |
43.24 (3.16) |
-92.69% | Details | |
| 3/21/2019 | Biogen | BIIB | Downgrade | Neutral (Buy) |
320.59 (226.06) |
-29.49% | Details | |
| 3/15/2019 | Rocket Pharmaceuticals | RCKT | New Coverage | Buy (N/A) |
15.10 (21.31) |
41.13% | Details | |
| 2/27/2019 | Karyopharm Therapeutics | KPTI | Downgrade | Underperform (Neutral) |
4.87 (9.65) |
98.15% | Details | |
| 1/30/2019 | Amgen | AMGN | Maintain | Buy (N/A) |
|
Details | ||
| 1/3/2019 | NewLink Genetics | NLNK | Downgrade | Underperform (Neutral) |
1.52 (0.89) |
-41.45% | Details | |
| 1/3/2019 | Karyopharm Therapeutics | KPTI | Upgrade | Neutral (Underperform) |
9.37 (4.87) |
-48.03% | Details | |
| 1/2/2019 | Moderna | MRNA | New Coverage | Buy (N/A) |
15.27 (19.76) |
29.4% | Details | |
| 11/2/2018 | Puma Biotechnology | PBYI | Downgrade | Underperform (Buy) |
38.60 (8.04) |
-79.17% | Details | |
| 10/29/2018 | Kodiak Sciences Inc. | KOD | New Coverage | Buy (N/A) |
9.56 (37.05) |
287.55% | Details | |
| 10/16/2018 | Y-mAbs Therapeutics | YMAB | New Coverage | Buy (N/A) |
20.81 (8.61) |
-58.63% | Details |
